Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?

Current Opinion in Rheumatology

Volumn 16, Issue 6, 2004, Pages 707-713

  Chinoy, Hector ^a   Ollier, William E R ^a   Cooper, Robert G ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

Dermatomyositis; Haplotypes; HLA; Idiopathic inflammatory myopathies; Immunogenetics; Inclusion body myositis; Microchimerism; Polymyositis

Indexed keywords

HLA DR ANTIGEN; MESSENGER RNA; NITRIC OXIDE SYNTHASE;

ALLOIMMUNITY; COHORT ANALYSIS; GENE EXPRESSION; GENETIC IDENTIFICATION; HUMAN; IDIOPATHIC DISEASE; IMMUNOGENETICS; IMMUNOPATHOGENESIS; MEDICAL EXAMINATION; MEDICAL RESEARCH; MYOSITIS; PRIORITY JOURNAL; REVIEW; ULTRAVIOLET RADIATION; UNITED KINGDOM;

ANIMALS; CHIMERISM; CYTOKINES; HLA ANTIGENS; HUMANS; MYOSITIS;

EID: 7044274716     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000142339.24380.b7     Document Type: Review

References (52)

1. Mastaglia FL, Phillips BA: Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002, 28:723-741.
2. Plotz PH, Rider LG, Targoff IN, et al.: NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995, 122:715-724.
3. Shamim EA, Rider LG, Miller FW: Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2000, 12:482-491.
4. Ollier W: The genetic basis of rheumatic disease. In Rheumatology, edn 3. Edited by Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Mosby; 2003:99-111.
5. Rider LG, Gurley RC, Pandey JP, et al.: Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 1998, 41:710-719.
6. Arnett FC, Targoff IN, Mimori T, et al.: Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996, 39:1507-1518.
7. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al.: Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257-1266.
8. Shamim EA, Rider LG, Pandey JP, et al.: Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002, 46:1885-1893.
9. Furuya T, Hakoda M, Higami K, et al.: Association of HLA class I and class II alleles with myositis in Japanese patients. J Rheumatol 1998, 25:1109-1114.
10. Rider LG, Shamim E, Okada S, et al.: Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999, 42:1285-1290.
11. Rider LG, Artlett CM, Foster CB, et al.: Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 2000, 121:47-52.
12. Pachman LM, Liotta-Davis MR, Hong DK, et al.: TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000, 43:2368-2377.
13. Luppi P, Rossiello MR, Faas S, Trucco M: Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med 1995, 73:381-393.
14. Cooper GS, Miller FW, Pandey JP: The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 1999, 107(suppl 5):693-700.
15. Hengstman GJ, van Venrooij WJ, Vencovsky J, et al.: The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000, 59:141-142.
16. Okada S, Weatherhead E, Targoff IN, et al.: Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003, 48:2285-2293. An important global collaboration from 15 countries looking at 919 IIM patients. The proportion of DM patients, versus all IIM patients, and the proportion of anti-Mi-2 antibodies, versus all MSAs, were found to correlate with UV intensity.
17. Mierau R, Dick T, Bartz-Bazzanella P, et al.: Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996, 39:868-876.
18. Hood E: The environment-autoimmune link. Environ Health Perspect 2003, 111:A274-A276.
19. Werth VP, Callen JP, Ang G, Sullivan KE: Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 2002, 119:617-620.
20. Tezak Z, Hoffman EP, Lutz JL, et al.: Gene expression profiling in DQA10501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154-4163.
21. Lutz J, Huwiler KG, Fedczyna T, et al.: Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF[alpha]-308A allele in children with juvenile dermatomyositis. Clin Immunol 2002, 103:260-263.
22. Hassan AB, Nikitina-Zake L, Sanjeevi CB, et al.: Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB103) with polymyositis and dermatomyositis. Arthritis Rheum 2004, 50:1013-1015. The authors demonstrate that the ancestral haplotype, together with MICAS.1/TNF2/TNFa2, is an important susceptibility factor for PM/DM.
23. Wiendl H, Mitsdoerffer M, Weller M: Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. Hum Immunol 2003, 64:1050-1056.
24. Wiendl H, Behrens L, Maier S, et al.: Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol 2000, 48:679-684.
25. Wiendl H, Mitsdoerffer M, Hofmeister V, et al.: The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 2003, 126:176-185. Using in vitro models, the authors studied HLA-G isoforms, and found that they are powerful inhibitors of the primary and secondary immune response in muscle.
26. Reed AM: Chimerism in myositis. Curr Rheumatol Rep 2003, 5:421-424.
27. Reed AM, Shock LP, Picornell YJ: Chimerism in children with JDM. Arthritis Rheum 1998, 41:3264.
28. Reed AM, Picornell YJ, Harwood A, Kredich DW: Chimerism in children with juvenile dermatomyositis. Lancet 2000, 356:2156-2157.
29. Artlett CM, Ramos R, Jiminez SA, et al.: Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 2000, 356:2155-2156.
30. Reed AM, Cragoe S, Kredich D, et al.: Juvenile dermatomyositis and maternal cell chimerism, how does it all begin? Arthritis Rheum 2001, 44:3213.
31. Artlett CM, Miller FW, Rider LG: Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. Rheumatology 2001, 40:1279-1284.
32. Artlett CM, O'Hanlon TP, Lopez AM, et al.: HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum 2003, 48:2567-2572.
33. Reed AM, McNallan K, Wettstein P, et al.: Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? J Immunol 2004, 172:5041-5046. The role of maternal microchimeric cells is studied in a large JDM cohort, and for the first time it is demonstrated that chimeric cells in JDM patients are reactive against host cells.
34. Lambert NC, Evans PC, Hashizumi TL, et al.: Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA10501: implications in autoimmunity. J Immunol 2000, 164:5545-5548.
35. Stevens AM: Foreign cells in polymyositis; could stem cell transplantation and pregnancy-derived chimerism lead to the same disease? Curr Rheumatol Rep 2003, 5:437-444.
36. Stevens AM, Sullivan KM, Nelson JL: Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatol 2003, 42:34-39. A fascinating retrospective review of patients undergoing hematopoietic stem cell transplantation over a 30-year period. The incidence of PM was found to be far higher than that of sporadic PM, supporting the alloimmune hypothesis.
37. Nelson JL: Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune? Arthritis Rheum 1996, 39:191-194.
38. Lampe JB, Gossrau G, Kempe A, et al.: Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol 2003, 250:1313-1317.
39. Askanas V, Engel WK: Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003, 15:737-744.
40. Askanas V, McFerrin J, Alvarez RB, et al.: Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport 1997, 8:2155-2158.
41. Askanas V, Engel WK, McFerrin J, Vattemi G: Transthyretin Val122Ile, accumulated Abeta, and inclusion-body myositis aspects in cultured muscle. Neurology 2003, 61:257-260. An elegant gene transfer experiment upregulating the IBM phenotype in muscle fibers of a patient expressing the TTR mutation.
42. Gossrau G, Gestrich B, Koch R, et al.: Apolipoprotein E and alpha-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis. Eur Neurol 2004, 51:215-220.
43. Greenberg SA, Sanoudou D, Haslett JN, et al.: Molecular profiles of inflammatory myopathies. Neurology 2002, 59:1170-1182.
44. Engel AG, Arahata K: Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984, 16:209-215.
45. Hofbauer M, Wiesener S, Babbe H, et al.: Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci USA 2003, 100:4090-4095.
46. Muntzing K, Lindberg C, Moslemi AR, Oldfors A: Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 2003, 58:195-200.
47. Serreze DV, Pierce MA, Post CM, et al.: Paralytic autoimmune myositis develops in nonobese diabetic mice made Th1 cytokine-deficient by expression of an IFN-gamma receptor beta-chain transgene. J Immunol 2003, 170:2742-2749.
48. Nguyen HX, Tidball JG: Expression of a muscle-specific, nitric oxide synthase transgene prevents muscle membrane injury and reduces muscle inflammation during modified muscle use in mice. J Physiol 2003, 550:347-356.
49. van der Meulen MF, Bronner IM, Hoogendijk JE, et al.: Polymyositis: an over-diagnosed entity. Neurology 2003, 61:316-321.
50. Hoffman EP, Brown KJ, Eccleston E: New molecular research technologies in the study of muscle disease. Curr Opin Rheumatol 2003, 15:698-707. A useful and informative review outlining future approaches in muscle disease investigation, summarizing techniques such as gene expression profiling and whole genome SNP association studies.
51. Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517.
52. Kruglyak L: Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet 1999, 22:139-144.